Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liu, G.
Right arrow Articles by Warner, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liu, G.
Right arrow Articles by Warner, E.

Journal of Clinical Oncology, Vol 15, 110-115, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Patient preferences for oral versus intravenous palliative chemotherapy

G Liu, E Franssen, MI Fitch and E Warner
Division of Oncology, Toronto Sunnybrook Regional Cancer Centre, Canada.

PURPOSE: To assess patient preference for oral versus intravenous (i.v.) palliative chemotherapy (CT). A strong preference would be an important quality-of-life issue. PATIENTS AND METHODS: A structured interviewer-administered scenario-based questionnaire evaluated incurable cancer patients who would be likely to receive palliative CT in the future. Using probability trade-offs, the preference for route of administration was evaluated against diminishing treatment response. RESULTS: Of 103 assessable patients, 92 preferred oral CT, 10 preferred i.v. CT, and one had no preference. Patient preferences were not associated with age, sex, site of primary cancer, or previous CT experiences. Major reasons for preferring oral CT were convenience, problems with i.v. access or needles, and a better CT-taking environment (outside of the clinic). Regardless of initial preference, 70% of patients were not willing to accept a lower response rate and 74% were not willing to accept a shorter duration of response to retain their initial preference. Although 99% of patients had a preference, 39% wanted the specific treatment decision made primarily by their physicians, 38% primarily by themselves, and 22% shared equally. CONCLUSION: Patients with incurable cancer have a clear preference for oral CT, but are generally not willing to sacrifice efficacy for their preference. Almost 40% of patients did not want to make final treatment decisions themselves.


This article has been cited by other articles:


Home page
 Ann OncolHome page
E. Casado, P. Pfeiffer, J. Feliu, M. Gonzalez-Baron, L. Vestermark, and H. A. Jensen
UFT (tegafur-uracil) in rectal cancer
Ann. Onc., August 1, 2008; 19(8): 1371 - 1378.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
I. M. Hennig, J. D. Naik, S. Brown, A. Szubert, D. A. Anthoney, D. P. Jackson, A. M. Melcher, S. M. Crawford, C. Bradley, J. M.B. Brown, et al.
Severe Sequence-Specific Toxicity When Capecitabine Is Given After Fluorouracil and Leucovorin
J. Clin. Oncol., July 10, 2008; 26(20): 3411 - 3417.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
E. Bolke, M. Peiper, W. Budach, D. Cunningham, and N. Starling
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
N. Engl. J. Med., May 1, 2008; 358(18): 1965 - 1965.
[Full Text] [PDF]

Home page
 Ann OncolHome page
M. Findlay, G. von Minckwitz, and A. Wardley
Effective oral chemotherapy for breast cancer: pillars of strength
Ann. Onc., February 1, 2008; 19(2): 212 - 222.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
D. Cunningham, N. Starling, S. Rao, T. Iveson, M. Nicolson, F. Coxon, G. Middleton, F. Daniel, J. Oates, A. R. Norman, et al.
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
N. Engl. J. Med., January 3, 2008; 358(1): 36 - 46.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. W. Hong, I.-H. Lee, Y. H. Kwak, Y. T. Park, H. C. Sung, I. C. Kwon, and H. Chung
Efficacy and tissue distribution of DHP107, an oral paclitaxel formulation
Mol. Cancer Ther., December 1, 2007; 6(12): 3239 - 3247.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. O'Brien, J. Eckardt, and R. Ramlau
Recent Advances with Topotecan in the Treatment of Lung Cancer
Oncologist, October 1, 2007; 12(10): 1194 - 1204.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. Bartsch, C. Wenzel, G. Altorjai, U. Pluschnig, M. Rudas, R. M. Mader, M. Gnant, C. C. Zielinski, and G. G. Steger
Capecitabine and Trastuzumab in Heavily Pretreated Metastatic Breast Cancer
J. Clin. Oncol., September 1, 2007; 25(25): 3853 - 3858.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. E. Broker, S. A. Veltkamp, E. I. Heath, B. C. Kuenen, H. Gall, L. Astier, S. Parker, L. Kayitalire, P. M. Lorusso, J. H.M. Schellens, et al.
A Phase I Safety and Pharmacologic Study of a Twice Weekly Dosing Regimen of the Oral Taxane BMS-275183
Clin. Cancer Res., July 1, 2007; 13(13): 3906 - 3912.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. R. Eckardt, J. von Pawel, J.-L. Pujol, Z. Papai, E. Quoix, A. Ardizzoni, R. Poulin, A. J. Preston, G. Dane, and G. Ross
Phase III Study of Oral Compared With Intravenous Topotecan As Second-Line Therapy in Small-Cell Lung Cancer
J. Clin. Oncol., May 20, 2007; 25(15): 2086 - 2092.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
J. Aisner
Overview of the changing paradigm in cancer treatment: Oral chemotherapy
Am. J. Health Syst. Pharm., May 1, 2007; 64(9_Supplement_5): S4 - S7.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
S. D Parsad and M. J Ratain
Prescribing oral chemotherapy
BMJ, February 24, 2007; 334(7590): 376 - 376.
[Full Text] [PDF]

Home page
 JCOHome page
M. E.R. O'Brien, T.-E. Ciuleanu, H. Tsekov, Y. Shparyk, B. Cucevia, G. Juhasz, N. Thatcher, G. A. Ross, G. C. Dane, and T. Crofts
Phase III Trial Comparing Supportive Care Alone With Supportive Care With Oral Topotecan in Patients With Relapsed Small-Cell Lung Cancer
J. Clin. Oncol., December 1, 2006; 24(34): 5441 - 5447.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
H.-J. Schmoll and D. Arnold
Update on Capecitabine in Colorectal Cancer
Oncologist, October 1, 2006; 11(9): 1003 - 1009.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J Cassidy
In response to: 'On prejudice and facts and choices', an editorial by Kohne and Folprecht
Ann. Onc., September 1, 2006; 17(9): 1469 - 1471.
[Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
I. Hyodo, K. Shirao, T. Doi, K. Hatake, Y. Arai, K. Yamaguchi, T. Tamura, S. Takemiya, H. Takiuchi, K. Nakagawa, et al.
A Phase II Study of the Global Dose and Schedule of Capecitabine in Japanese Patients with Metastatic Colorectal Cancer
Jpn. J. Clin. Oncol., July 1, 2006; 36(7): 410 - 417.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
D. Crivellari, D. Lombardi, G. Corona, C. Massacesi, R. Talamini, R. Sorio, M. D. Magri, C. Lestuzzi, A. Lucenti, A. Veronesi, et al.
Innovative schedule of oral idarubicin in elderly patients with metastatic breast cancer: comprehensive results of a phase II multi-institutional study with pharmacokinetic drug monitoring
Ann. Onc., May 1, 2006; 17(5): 807 - 812.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Baweja, V. J. Suman, T. R. Fitch, J. A. Mailliard, A. Bernath, K. M. Rowland, S. R. Alberts, J. S. Kaur, and E. A. Perez
Phase II trial of oral vinorelbine for the treatment of metastatic breast cancer in patients >=65 years of age: an NCCTG study
Ann. Onc., April 1, 2006; 17(4): 623 - 629.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
W. B. Ershler
Capecitabine monotherapy: safe and effective treatment for metastatic breast cancer.
Oncologist, April 1, 2006; 11(4): 325 - 335.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. E. Broker, F. Y.F.L. de Vos, C. J. van Groeningen, B. C. Kuenen, H. E. Gall, M. H. Woo, M. Voi, J. A. Gietema, E. G.E. de Vries, and G. Giaccone
Phase I Trial with BMS-275183, a Novel Oral Taxane with Promising Antitumor Activity.
Clin. Cancer Res., March 15, 2006; 12(6): 1760 - 1767.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. H. Partridge
Non-adherence to endocrine therapy for breast cancer
Ann. Onc., February 1, 2006; 17(2): 183 - 184.
[Full Text] [PDF]

Home page
 Ann OncolHome page
C.-H. Kohne and G. Folprecht
On prejudice and facts and choices
Ann. Onc., February 1, 2006; 17(2): 185 - 187.
[Full Text] [PDF]

Home page
 Ann OncolHome page
L. Fallowfield, L. Atkins, S. Catt, A. Cox, C. Coxon, C. Langridge, R. Morris, and M. Price
Patients' preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer
Ann. Onc., February 1, 2006; 17(2): 205 - 210.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
F. Nole, C. Catania, G. Sanna, K. Imadalou, E. Munzone, L. Adamoli, B. Longerey, G. Blanchot, and A. Goldhirsch
Dose-finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer
Ann. Onc., February 1, 2006; 17(2): 322 - 329.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C. Twelves, S. Gollins, R. Grieve, and L. Samuel
A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer
Ann. Onc., February 1, 2006; 17(2): 239 - 245.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. Kaufmann, K. Spieth, U. Leiter, C. Mauch, P. von den Driesch, T. Vogt, R. Linse, W. Tilgen, D. Schadendorf, J. C. Becker, et al.
Temozolomide in Combination With Interferon-Alfa Versus Temozolomide Alone in Patients With Advanced Metastatic Melanoma: A Randomized, Phase III, Multicenter Study from the Dermatologic Cooperative Oncology Group
J. Clin. Oncol., December 10, 2005; 23(35): 9001 - 9007.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
A. L. Visbal, N. B. Leighl, R. Feld, and F. A. Shepherd
Adjuvant Chemotherapy for Early-Stage Non-small Cell Lung Cancer
Chest, October 1, 2005; 128(4): 2933 - 2943.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
H. Takiuchi, H. Narahara, T. Tsujinaka, M. Gotoh, S.-i. Kawabe, K.-i. Katsu, H. Iishi, M. Tatsuta, K. Fujitani, H. Furukawa, et al.
Phase I Study of S-1 Combined with Irinotecan (CPT-11) in Patients with Advanced Gastric Cancer (OGSG 0002)
Jpn. J. Clin. Oncol., September 1, 2005; 35(9): 520 - 525.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Seck, S. Riemer, R. Kates, T. Ullrich, V. Lutz, N. Harbeck, M. Schmitt, M. Kiechle, R. Diasio, and E. Gross
Analysis of the DPYD Gene Implicated in 5-Fluorouracil Catabolism in a Cohort of Caucasian Individuals
Clin. Cancer Res., August 15, 2005; 11(16): 5886 - 5892.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
C. Twelves, A. Wong, M. P. Nowacki, M. Abt, H. Burris III, A. Carrato, J. Cassidy, A. Cervantes, J. Fagerberg, V. Georgoulias, et al.
Capecitabine as Adjuvant Treatment for Stage III Colon Cancer
N. Engl. J. Med., June 30, 2005; 352(26): 2696 - 2704.
[Abstract] [Full Text] [PDF]

Home page
 Neuro OncolHome page
J.-B. Wasserfallen, S. Ostermann, S. Leyvraz, and R. Stupp
Cost of temozolomide therapy and global care for recurrent malignant gliomas followed until death
Neuro-oncol, April 1, 2005; 7(2): 189 - 195.
[Abstract] [PDF]

Home page
 The OncologistHome page
R. J. Gralla
Quality-of-Life Considerations in Patients with Advanced Lung Cancer: Effect of Topotecan on Symptom Palliation and Quality of Life
Oncologist, December 1, 2004; 9(suppl_6): 14 - 24.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
Y. S. Hong, S. Y. Song, S. I. Lee, H. C. Chung, S. H. Choi, S. H. Noh, J. N. Park, J. Y. Han, J. H. Kang, K. S. Lee, et al.
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer
Ann. Onc., September 1, 2004; 15(9): 1344 - 1347.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
J. J. Lee, T. M. Kim, S. J. Yu, D.-W. Kim, Y.-h. Joh, D.-Y. Oh, J. H. Kwon, T. Y. Kim, D. S. Heo, Y.-J. Bang, et al.
Single-agent Capecitabine in Patients with Metastatic Colorectal Cancer Refractory to 5-Fluorouracil/Leucovorin Chemotherapy
Jpn. J. Clin. Oncol., July 1, 2004; 34(7): 400 - 404.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Salazar, D. Bissett, C. Twelves, L. Breimer, M. DeMario, S. Campbell, J. Zhi, S. Ritland, and J. Cassidy
A Phase I Clinical and Pharmacokinetic Study of Ro 31-7453 Given as a 7- or 14-Day Oral Twice Daily Schedule Every 4 Weeks in Patients with Solid Tumors
Clin. Cancer Res., July 1, 2004; 10(13): 4374 - 4382.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. E. R. O'Brien, A. Szczesna, H. Karnicka, P. Zatloukal, T. Eisen, W. Hartmann, P. Kasan, B. Longerey, and F. Lefresne
Vinorelbine alternating oral and intravenous plus carboplatin in advanced non-small-cell lung cancer: results of a multicentre phase II study
Ann. Onc., June 1, 2004; 15(6): 921 - 927.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. A. Rich, R. C. Shepard, and S. T. Mosley
Four Decades of Continuing Innovation With Fluorouracil: Current and Future Approaches to Fluorouracil Chemoradiation Therapy
J. Clin. Oncol., June 1, 2004; 22(11): 2214 - 2232.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
R. B. Diasio
Adjuvant Chemotherapy for Adenocarcinoma of the Lung -- Is the Standard of Care Ready for Change?
N. Engl. J. Med., April 22, 2004; 350(17): 1777 - 1779.
[Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
Y. Kondo, M. Terashima, A. Sato, and T. Taguchi
A Pilot Phase II Study of Capecitabine in Advanced or Recurrent Colorectal Cancer
Jpn. J. Clin. Oncol., April 1, 2004; 34(4): 195 - 201.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol Pharm PractHome page
M. Summerhayes
The impact of workload changes and staff availability on IV chemotherapy services
Journal of Oncology Pharmacy Practice, December 1, 2003; 9(4): 123 - 128.
[Abstract] [PDF]

Home page
 Ann OncolHome page
W. Scheithauer, J. McKendrick, S. Begbie, M. Borner, W. I. Burns, H. A. Burris, J. Cassidy, D. Jodrell, P. Koralewski, E. L. Levine, et al.
Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial
Ann. Onc., December 1, 2003; 14(12): 1735 - 1743.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Zhou, Z.-Y. Tang, J. Fan, Z.-Q. Wu, Y. Ji, Y.-S. Xiao, Y.-H. Shi, X.-M. Li, Q.-M. Sun, Y.-K. Liu, et al.
Capecitabine Inhibits Postoperative Recurrence and Metastasis after Liver Cancer Resection in Nude Mice with Relation to the Expression of Platelet-Derived Endothelial Cell Growth Factor
Clin. Cancer Res., December 1, 2003; 9(16): 6030 - 6037.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. Jassem, P. Kosmidis, R. Ramlau, K. Zarogoulidis, L. Novakova, J. Breton, P.-L. Etienne, C. Seebacher, M. Grivaux, A. Ojala, et al.
Oral vinorelbine in combination with cisplatin: a novel active regimen in advanced non-small-cell lung cancer
Ann. Onc., November 1, 2003; 14(11): 1634 - 1639.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
X. Pivot, E. Chamorey, E. Guardiola, N. Magne, A. Thyss, J. Otto, B. Giroux, Z. Mouri, M. Schneider, and G. Milano
Phase I and pharmacokinetic study of the association of capecitabine-cisplatin in head and neck cancer patients
Ann. Onc., October 1, 2003; 14(10): 1578 - 1586.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Gelderblom, R. Salazar, J. Verweij, G. Pentheroudakis, M. J. A. de Jonge, M. Devlin, C. van Hooije, F. Seguy, R. Obach, J. Prunonosa, et al.
Phase I Pharmacological and Bioavailability Study of Oral Diflomotecan (BN80915), a Novel E-Ring-modified Camptothecin Analogue in Adults with Solid Tumors
Clin. Cancer Res., September 15, 2003; 9(11): 4101 - 4107.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Freyer, T. Delozier, M. Lichinister, D. Gedouin, P. Bougnoux, P. His, K. Imadalou, and V. Trillet-Lenoir
Phase II Study of Oral Vinorelbine in First-Line Advanced Breast Cancer Chemotherapy
J. Clin. Oncol., January 1, 2003; 21(1): 35 - 40.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. M. Hoff, E. D. Saad, J. A. Ajani, Y. Lassere, C. Wenske, D. Medgyesy, S. Dwivedy, M. Russo, and R. Pazdur
Phase I Study with Pharmacokinetics of S-1 on an Oral Daily Schedule for 28 Days in Patients with Solid Tumors
Clin. Cancer Res., January 1, 2003; 9(1): 134 - 142.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. J. Hobday, J. W. Kugler, M. R. Mahoney, D. J. Sargent, J. A. Sloan, T. R. Fitch, J. E. Krook, M. J. O'Connell, J. A. Mailliard, M. T. Tirona, et al.
Efficacy and Quality-of-Life Data Are Related in a Phase II Trial of Oral Chemotherapy in Previously Untreated Patients With Metastatic Colorectal Carcinoma
J. Clin. Oncol., December 1, 2002; 20(23): 4574 - 4580.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
C.M.F. Kruijtzer, J.H. Beijnen, and J.H.M. Schellens
Improvement of Oral Drug Treatment by Temporary Inhibition of Drug Transporters and/or Cytochrome P450 in the Gastrointestinal Tract and Liver: An Overview
Oncologist, December 1, 2002; 7(6): 516 - 530.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. D. Seidman and M. Aapro
Introduction
Oncologist, December 1, 2002; 7(90006): 1 - 3.
[Full Text] [PDF]

Home page
 The OncologistHome page
A. D. Seidman, J. O'Shaughnessy, and J.-L. Misset
Single-Agent Capecitabine: A Reference Treatment for Taxane-Pretreated Metastatic Breast Cancer?
Oncologist, December 1, 2002; 7(90006): 20 - 28.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. Malet-Martino and R. Martino
Clinical Studies of Three Oral Prodrugs of 5-Fluorouracil (Capecitabine, UFT, S-1): A Review
Oncologist, August 1, 2002; 7(4): 288 - 323.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Hudes
Boosting Bioavailability of Topotecan: What Do We Gain?
J. Clin. Oncol., July 1, 2002; 20(13): 2918 - 2919.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. J. Cohen, C. G. Leichman, G. Yeslow, M. Beard, A. Proefrock, B. Roedig, B. Damle, S. P. Letrent, A. P. DeCillis, and N. J. Meropol
Phase I and Pharmacokinetic Study of Once Daily Oral Administration of S-1 in Patients with Advanced Cancer
Clin. Cancer Res., July 1, 2002; 8(7): 2116 - 2122.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
A. H. Partridge, J. Avorn, P. S. Wang, and E. P. Winer
Adherence to Therapy With Oral Antineoplastic Agents
J Natl Cancer Inst, May 1, 2002; 94(9): 652 - 661.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. Feliu, J. Calvillo, A. Escribano, J. de Castro, M. E. Sanchez, A. Mata, E. Espinosa, A. Garcia Grande, A. Mateo, and M. Gonzalez Baron
Neoadjuvant therapy of rectal carcinoma with UFT-leucovorin plus radiotherapy
Ann. Onc., May 1, 2002; 13(5): 730 - 736.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. J.A. de Jonge, C. J.A. Punt, A. Sparreboom, A. S.T. Planting, M.E.W.J. Peters, J. van de Schraaf, A. Jackman, R. Smith, P. H.M. de Mulder, and J. Verweij
Phase I and Pharmacologic Study of Oral ZD9331, A Novel Nonpolyglutamated Thymidylate Synthase Inhibitor, in Adult Patients With Solid Tumors
J. Clin. Oncol., April 1, 2002; 20(7): 1923 - 1931.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol Pharm Pract